Application of ER and Ki-67 expression ratio in EC and AH retention fertility function treatment prognosis

Abstract

The invention discloses an application of an ER and Ki-67 expression ratio in endometrial tissues in fertility function retention treatment prognosis of endometrial cancer (EC) and atypical endometrial hyperplasia (AH). According to the invention, 53 EC patients and 68 AH patients orally take MPA or MA, then gonadotropin is combined to release a hormone agonist and / or a levoynorethindrone intrauterine sustained release system, the patients are divided into a recurrence group and a non-recurrence group according to whether recurrence occurs after complete remission, then ER, PR, P16, P53, PTEN, Ki-67 and the like are subjected to immunohistochemical analysis, and statistical analysis is carried out. Results show that the expression rate of the Ki-67 is of great significance in predicting recurrence after the EC and AH retention fertility function treatment, and the optimal critical value (3.55) of ER / Ki-67 can predict recurrence after the EC and AH retention fertility function treatment better than that of a single immunohistochemical marker. The method has an important application value.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the application of the expression ratio of ER and Ki-67 in endometrial tissue in the prognosis of endometrial cancer (EC) and endometrial atypical hyperplasia (AH) with fertility-preserving treatment. Background technique [0002] Studies have shown that EC may develop from precursor lesions, mainly AH, and 29% of untreated AH patients may develop cancer. The mainstay of treatment for AH and EC is surgery, however, many EC patients are diagnosed under the age of 44, so surgery is not the best option, especially for nulliparous women who wish to preserve uterine fertility. According to reports, the remission rate of EC patients receiving progestin-based conservative treatment is 50-80%, and the pregnancy rate is 25-30%, however, the recurrence rate is as high as 24-40%. Therefore, it has been the focus of clinical research to find out the factors of recurrence in EC patient...

AI Technical Summary

Problems solved by technology

The mainstay of treatment for AH and EC is surgery, however, many EC patients are diagnosed under the age of 44, so surgery is not the best option, especially for nulliparous women who wish to preserve the fertility of the uterus

It has been reported that the remission rate of EC patients receiving progestin-based conservative treatment is 50-80%, and the pregnancy rate is 25-30%, however, the recurrence rate is as high as 24-40%

Therefore, it has always been the focus of clinical research to find out the factors of recurrence in EC patients or AH patients after fertility-preserving treatment, and the indicators related to whether EC patients or AH patients relapse after fertility-preserving treatment are still unknown

Images